International Stem Cell Corp. (ISCO)

[236T568]

actually, no

a cosmetics company with flat or decreasing revenues would NOT command a P/E of 40x

more like 12x at the most

and if ISCO stopped ALL R&D then it would still have a Net Loss of about $3.3 million for the year, based on the recently issued 2017 financials

currently ISCO is way overvalued, look for sub $1.00 prices in the future

A PE of 40 is not unrealistically high for a small slowly growing company. If we assumed the total effective outstanding share quantity is 30 million shares, and the company stopped all research and focused only on their revenue generating units that had 1.4 million in earnings, a PE of 40 would be associated with a stock price of about $1.87/share.